Please assess the completion status of the following clinical trial:

Trial Title: S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the oropharynx by biopsy or fine needle aspiration of the primary lesion or neck mass~  * Selected stage III or IV disease~    * No T1-2, N1 disease~   * No T4b disease~ * No other primary tumor sites or unknown primary tumor sites~ * Previously untreated disease~* Measurable or non-measurable disease by clinical exam, CT scan or MRI~* Disease considered to be curatively resectable~  * Patients for whom surgical excision is unlikely to result in clear margins are not eligible, including patients with any of the following:~    * Gross extension of tumor to skull base (e.g., T4b disease)~   * Severe trismus~   * Pterygoid plate erosion~   * Sphenoid bone or foramen ovale involvement~   * Direct extension to involve prevertebral-fascia~   * Extension to superior nasopharynx or eustachian tube~   * Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)~   * Suspected invasion (encasement) of the common or internal carotid arteries (T4b)~   * Direct extension of neck disease to involve the external skin~   * Regional metastases to the supraclavicular neck (IVB low level VB nodes)~* Disease must be appropriate for definitive radiotherapy with curative intent~* No evidence of distant metastases (M1)~  * Must have negative chest x-ray~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* No myocardial infarction within the past 3 months~* No unstable or uncontrolled angina~* No active systemic infection~* Granulocyte count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~* Creatinine \< 1.5 mg/dL~* Bilirubin normal~* Alkaline phosphatase ≤ 2 times upper limit of normal (ULN)~* SGOT or SGPT ≤ 1.5 times ULN~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No history of hypersensitivity reaction to products containing polysorbate 80~* No medical contraindication to surgery as defined by the treating institution~* No clinically significant motor or sensory neuropathy ≥ grade 2~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer from which the patient is in complete remission~PRIOR CONCURRENT THERAPY:~* No prior therapeutic surgery for head and neck cancer~* No prior radiotherapy~* No prior chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cisplatin/RT alone (Type: ACTIVE_COMPARATOR): cisplatin and radiation therapy
- induction chemo followed by cisplatin/RT (Type: EXPERIMENTAL): docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval